Skip to content

Mechanism and Immune Function Analysis of SARS-CoV-2 Infection in Hematologic Tumors

Mechanism and Immune Function Analysis of SARS-CoV-2 Infection in Hematologic Tumors and Discovery of Potential Drug Targets

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05683353
Enrollment
60
Registered
2023-01-13
Start date
2022-12-14
Completion date
2027-12-01
Last updated
2026-09-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hematologic Malignancy, SARS-CoV-2 Infection

Keywords

SARS-CoV-2 infection, hematologic malignancy, leukemia, interaction, immune function, network analysis

Brief summary

The goal of this observational study is to compare the immune function and infection mechanism of patients with hematologic tumors and those people without underlying diseases after infection with SARS-CoV-2. Clinical characteristics, treatment options and responses will be collected. Peripheral blood will be collected from patients with hematologic tumors infected with SARS-CoV-2 and those people without underlying diseases infected with SARS-CoV-2.

Detailed description

To establish a retrospective and prospective cohort of patients with hematologic tumors infected with SARS-CoV-2 and people without underlying diseases infected with SARS-CoV-2. Firstly, peripheral blood samples will be collected at infection time points and after SARS-CoV-2 nucleic acid testing turns negative. Subsequently, the transcriptome sequencing and immunological experiments will be performed to analyze the differentially expressed genes, immune function of cells, etc. Comparative analysis: 1. To compare the immune function of patients with hematologic tumors and those without underlying diseases after infection with SARS-CoV-2. 2. The transcriptomic and proteomic changes of patients with hematologic tumors are compared with those without underlying diseases after infection with SARS-CoV-2. 3. From the perspective of complex (human protein interaction subnetwork), the dynamic change process of SARS-CoV-2-targeted human protein complex (periodic complex) was deeply explored, in order to further analyze its potential dynamic infection mechanism and provide new clues for the discovery of drug targets.

Interventions

OTHERNone intervention

None intervention.

Sponsors

Peking University First Hospital
Lead SponsorOTHER

Study design

Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

\- Clinical diagnosis of hematologic tumors Clinical diagnosis of SARS-CoV-2 infection

Exclusion criteria

\- Severe diseases associated with other systems

Design outcomes

Primary

MeasureTime frameDescription
Mechanism and Immune Function Analysis of SARS-CoV-2 Infection in Hematologic Tumors1 yearTo compare the infection mechanism and immune function of patients with hematologic tumors infected with SARS-CoV-2 and people infected with SARS-CoV-2 without underlying diseases.

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Sep 17, 2026